Daxxify (daxibotulinumtoxinA-Ianm) is the first neurotoxin FDA approved in September 2022 for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults ages 18 and older. This neurotoxin longevity is twice the length of other neurotoxins. Lasting 6-9 months on average for most patients. The effects will gradually wear away before another appointment is needed.